The influence of the nonleaving group on the anticancer activity of tetrachlorido platinum(IV) complexes with pyridine/bipyridine derivatives

Add time:08/05/2019    Source:sciencedirect.com

Due to their inertness, platinum(IV) complexes are well known potential candidates to improve the pharmacological properties and selective cellular uptake of commonly used platinum(II) anticancer agents. In these 6-coordinate prodrugs, the equatorial nonleaving groups are the only ligands which remain in the final Pt-DNA adducts and directly affect the DNA binding property. In an effort to discover the structure–activity relationship; in this report, two novel platinum(IV) complexes, trans-[Pt(3phpy)2Cl4] (1) and [Pt(4dtb-bpy)Cl4].DMSO (2) (3phpy = 3-phenylpyridine and 4dtb-bpy = 4,4′-di-tert-butyl-2,2′-bipyridine) were prepared and fully characterized. Their in vitro activity was evaluated and compared with those of similar platinum(IV) complexes, containing unbranched ligands, trans-[Pt(py)2Cl4] and [Pt(bpy)Cl4]. Interestingly, complex 1, with phenylpyridine nonleaving ligands, demonstrated further antiproliferative properties among the studied platinum(IV) prodrugs. Moreover, the apoptosis rate in cell lines was also determined using flow cytometry. Furthermore, the resistance factor of complexes 1 and 2 were 1.1 and 1.3, respectively, using wild-type and cisplatin-resistant A2780 cell lines.

We also recommend Trading Suppliers and Manufacturers of PLATINUM (IV) BROMIDE (cas 13455-11-3). Pls Click Website Link as below: cas 13455-11-3 suppliers

Prev:Nitrogen and phosphorus co-doped carbon nanosheets as efficient counter electrodes of dye-sensitized solar cells
Next:Development of a series of 4-hydroxycoumarin platinum(IV) hybrids as antitumor agents: Synthesis, biological evaluation and action mechanism investigation)